IL17A and inflammatory bowel disease: To date, the pathophysiological mechanisms underlying these paradoxical effects are not well-defined, there is limited real-world data demonstrating the association between IL-17 inhibitor therapy and the onset of IBD, and there are no clear guidelines for the management of patients who experience these adverse events.